Source - RNS
RNS Number : 3975B
Integumen PLC
20 September 2018


20 September 2018


Integumen plc


("Integumen" or "the Company")

Update : details of legal demand; finalisation of Placing and Subscription

This announcement replaces 1868B issued at 700am on 19 September. The change relates to correcting details of the c11% shareholder in Integumen.


The Company announced in its Interim Report on 29 August 2018 that it is seeking to divest itself of under-performing assets, and further that the Company had declined an offer for its skin care division received from Mr Donald Nicholson as it seriously undervalued the assets being sought for purchase, many of which were not for sale.

Subsequently, the Company has received a formal demand for payment of certain amounts due and claimed to be due to Mr. Nicholson and Mercuriali Limited, for services provided to the Company.  Mercuriali is owned by Mr Nicholson. Mercuriali is a majority shareholder in Enhance Skin Products, Inc which is a c11% shareholder in Integumen.

Whilst the Board acknowledges that certain of the claimed amounts are owed to Mr Nicholson and Mercurali, it notes that Mr Nicholson, on behalf of himself and Mercuriali, previously agreed  that these amounts are not due to be paid before 9 July 2019.

In addition the formal notice seeks payment of debts owed by Integumen Inc, one of Integumen plc's subsidiaries, to third parties.

The Company  believe these demands for immediate payment are without merit, and it will strongly contest such claims if pursued.

The Board expects to complete the final elements of the Subscription, the Placing and acquisition of a stake in Cellulac plc, as announced on 16 July 2018 (and updated on 19 July 2018 and 24 July 2018), shortly.


Integumen plc

Gerard Brandon, Chief Executive


+44 (0) 1223 926 660  

SPARK Advisory Partners Limited

(Nominated Adviser)


Neil Baldwin/Andrew Emmott

+44 (0) 113 370 8974

Hybridan LLP  (Broker)

Claire Noyce

+44 (0) 20 3764 2341



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit